CoQ10 Ubiquinol vs Ubiquinone: What the Absorption Studies Show

One molecule, two oxidation states

Coenzyme Q10 is a benzoquinone ring with a tail of ten isoprene units, which is where the 10 in the name comes from and why the molecule weighs 863 daltons. The ring is the working end. In ubiquinone it carries two carbonyl oxygens, and in ubiquinol those same positions hold hydroxyl groups, which is the whole difference between the two products on the shelf. Getting from one to the other takes two electrons and two protons, and the reaction runs in both directions inside a cell. That two-electron swap is the entire job. CoQ10 shuttles electrons from complexes I and II to complex III in the respiratory chain, cycling between the forms thousands of times a second in a busy tissue, and the same chemistry makes ubiquinol a lipid-soluble antioxidant that can hand a hydrogen to a radical and take one back later.

The difference printed on the label is two hydrogen atoms.

The body runs the conversion either way

Swallow ubiquinone and cells reduce it. Swallow ubiquinol and some of it survives absorption as is. Either way, the fraction that reaches plasma travels mostly in the reduced form, bound to lipoproteins, and the ratio of ubiquinol to total CoQ10 in blood stays fairly steady. A three-way crossover in 21 adults aged 65 to 74 made that point directly. After a single 100 mg dose, none of the three formulations changed the redox status of what showed up in plasma, and CoQ10 appeared mostly as ubiquinol even when it went in as ubiquinone. The bottleneck sits at absorption, well before that step. CoQ10 is greasy and poorly water soluble, so uptake depends on bile, pancreatic enzymes and a meal with fat in it, and plasma peaks near 6 hours before a second bump around 24 hours as the liver recycles what it took up.

Absorption is the only place the two forms can plausibly part company.

What the head to head trials measured

The most cited study gave 12 healthy volunteers 200 mg a day of ubiquinone for 4 weeks, washed out for 4 weeks, then 200 mg a day of ubiquinol for 4 weeks. Total plasma CoQ10 rose from 0.9 to 2.5 µg/mL on ubiquinone and from 0.9 to 4.3 µg/mL on ubiquinol. The report doesn't describe blinding, and everyone took ubiquinone first, so order and expectation both run one way. A second crossover gave 10 older men 200 mg a day of each form for 2 weeks in random order, and total CoQ10 rose 1.5-fold on ubiquinol, from 1.3 to 3.4 µmol/L, while ubiquinone didn't move the number significantly. Six of the 10 men responded better to ubiquinol, two responded better to the other form, and neither study measured anything but blood levels. A three-period crossover in 21 older adults later added a water-soluble syrup and found it delivered 2.4 times the exposure of a ubiquinone capsule (95% CI 1.3 to 4.5), with the ubiquinol capsule at 1.7-fold and an interval crossing 1 (0.9 to 3.1).

Ten people in one trial. Twelve in the other.

Who paid, and what it bought

Each of those studies came out of a lab funded by, or working with, the manufacturer of the product that did best. The 2014 comparison was funded by Kaneka, the company that developed commercial ubiquinol. The elderly crossover that found a 2.4-fold advantage for a syrup was testing the sponsor's own formulation, and a 2026 single-dose study in 12 adults, funded by Cocrystal Health, reported a 2.20 ratio for peak concentration with an interval on the extrapolated AUC running from 1.47 to 8.00. None of these papers looks fabricated, and the direction of the results repeats. What repeats less reliably is the size of the gap. Then there's price: ubiquinol sells at roughly two to three times the ubiquinone cost per milligram, so a 1.7-fold gain bought at 2.5 times the price isn't a gain once you divide by cost.

Plasma concentration every time. Never a symptom, never a hospital admission.

Where the clinical evidence stands

Here the picture flips, because the trial with a hard endpoint used ubiquinone. Q-SYMBIO randomised 420 patients with moderate to severe heart failure to 100 mg of ubiquinone three times daily or placebo for 2 years, and the composite of major adverse cardiovascular events came in at 15% against 26%, hazard ratio 0.50 with a 95% interval of 0.32 to 0.80. Cardiovascular death was 9% against 16%, all cause death 10% against 18%. That trial was funded by Pharma Nord, which sells the formulation used, and nobody has replicated it at that size. The statin muscle data are negative. Forty-four patients with a history of simvastatin myalgia took 200 mg of CoQ10 or placebo for 12 weeks while simvastatin was titrated upward, and myalgia scores, tolerance of 40 mg and persistence on treatment were statistically indistinguishable.

Neither of those trials used ubiquinol.

No head to head study has compared the two forms on any outcome a patient would notice. The absorption gap looks real and small, and whether closing it changes anything is a question nobody has funded.

Frequently asked questions

Is ubiquinol better absorbed than ubiquinone?

On average, yes, in the studies that compared them directly. The gaps ran from no significant difference at 100 mg up to roughly 2-fold at 200 mg, in groups of 10 to 21 people.

Does the body convert ubiquinone into ubiquinol?

Yes. The reduction happens after absorption, and plasma carries CoQ10 mostly in the reduced form whichever version was on the label.

Should I take ubiquinol after 40?

Age is the argument the marketing leans on, and it rests on something real, since plasma CoQ10 declines with age. The trials in older adults are the same pharmacokinetic studies of 10 to 21 people. Nothing shows a clinical difference by age group.

How much CoQ10 did the trials use?

100 mg to 300 mg per day. Q-SYMBIO used 300 mg split into three doses, and the absorption studies used 100 mg or 200 mg once daily with food.

Does CoQ10 have side effects?

Trials have run to 900 mg per day for months without a safety signal beyond mild digestive complaints. It can lower blood pressure a little and may blunt warfarin, so anyone on either should raise it with their clinician.

---

This article is for general information only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Talk with your health care provider before using CoQ10, especially if you take prescription medication.

Sources

• Bioavailability of CoQ10 formulations in healthy elderly adults, Nutrients 2020
• Langsjoen PH, Langsjoen AM, Plasma CoQ10 with ubiquinol versus ubiquinone, Clin Pharmacol Drug Dev 2014
• Zhang Y et al., Ubiquinol is superior to ubiquinone in older men, Food Funct 2018
• Mei X et al., Cocrystal ubiquinol versus ubiquinone bioavailability, Clin Pharmacol Drug Dev 2026
• Mortensen SA et al., Q-SYMBIO: CoQ10 in chronic heart failure, JACC Heart Fail 2014
• Young JM et al., CoQ10 and simvastatin-induced myalgia, Am J Cardiol 2007